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Abstract: Genomic imprinting is a process resulting in the preferential expression of certain genes
depending on whether the genetic material has been inherited from the mother or the father. Many
imprinted genes have been identified as having important roles in mammalian development, and the
loss of imprints as well as non-imprinted alleles causes a variety of developmental abnormalities and
pathological conditions in both mice and humans. In this article, the phenomenon of genomic
imprinting, the developmental implications of imprinting and the molecular mechanisms proposed for
this process are reviewed.
Key Words: Genomic imprinting, Preferential gene expression, Gene regulation

Genomik İmprinting: Özel Bir Gen Regülasyonu Şekli
Özet: Genomik imprinting işlemi genetik materyalin anneden veya babadan kalıtılmış olmasına dayalı
olarak belirli genlerin tercihli olarak ifade edilmesidir. İmprinting etkisi altında olan çok sayıda genin
memelilerin gelişiminde önemli rol oynadığı tespit edilmiştir ve buna bağlı olarak imprinting etkisi
altında olan alleller kadar olmayan allellerin kaybı da farelerde ve insanlarda çok çeşitli gelişim
bozukluklarına ve hastalıklara neden olmaktadır. Bu makalede, genomik imprinting olgusu,
imprinting'in sebep olduğu gelişim bozuklukları ve imprinting işlevinde rol oynayabileceği ileri sürülen
moleküler mekanizmaların derlemesi yapılmıştır.
Anahtar Sözcükler: Genomik imprinting, Tercihli gen ifadesi, Gen düzenlenmesi

The Phenomenon of Genomic Imprinting
Although there is an absolute requirement for both a maternal and a paternal genome for
normal development, some homologous chromosomes are marked with epigenetic information
resulting in specific functional differences between parental genomes. As a result, only one
parental copy is active in the developing embryo and adult. This phenomenon is known as
genomic imprinting, and there is good evidence that genomic imprinting occurs at multiple
levels: initiating in the germ line, continuing after fertilization and maintained through
subsequent cell divisions during development (1, 2). Studies in mice have demonstrated that
the paternal genome is more important for the development of placental tissues
(extraembryonic membranes), while the maternal genome retains the crucial control of events
in the development of the embryo itself (3).
* Current adress: Hacettepe University, Faculty of Pharmacy Department of Pharmaceutical Biotechnology
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With the use of several different techniques, such as nuclear transplantation, balanced
translocation and transgenic mice generation, four imprinted genes have been identified to date
in the mouse. The insulin-like growth factor 2 (Igf2) and the H19 gene, which lie 90 kb apart
on chromosome 7, are both imprinted, but in opposite directions. The H19 gene is maternally
expressed, whereas Igf2 is expressed paternally. The insulin-like growth factor type-2 receptor
(Igf2r) on mouse chromosome 17 is maternally expressed. The most recently identified
imprinted gene is the small nuclear ribonucleoprotein polypeptide N gene (snrpN) that is also
located on chromosome 7. Its expression is paternal. In humans, the H19, Igf2 and human
snrpN genes have all been shown to be imprinted (4, 5). It has been demonstrated that genomic
imprinting plays a role in human genetic disease and cancer, and it has been suggested as an
alternative mode of inheritance (6, 7).
Available data indicate that genomic imprinting is functional in a large group of organisms
under different circumstances. These are:
a- Heterochromatization and inactivation of the X chromosome in mammals (8, 9).
b- Mating-type interconversion (strand-dependent switching of mating type) in yeast (10).
c- Hiding genetic variation in hybrid plants (11).
d- Embryo-endosperm differentiation in maize (12).
e- Gene activation and tumorigenesis in mammals (13).
f- Genetic disorders in humans (14, 15).
g- Differential methylation of transgenes in the mouse (16).
The Developmental Implications of Genomic Imprinting
Extensive studies have established that development in mammals is influenced by genomic
imprinting and the phenomenon of imprinting could account for congenital anomalies and
growth disorders (17, 18). The developmental implications of genomic imprinting are observed
at several levels:
Chromosomal Disorders (Uniparental Disomy): Observations of aberrant development of
embryos with only maternal or paternal genetic information in mice gave the first and the most
general indications of the existence of genomic imprinting in mammals. It was demonstrated
that duplication of certain chromosomes from one parent, called uniparental disomy, causes
embryonic lethality and problems with growth and viability (19). Studies in mice have revealed
that isoparental embryos die during midgestation stages. An example of such a situation in
humans is that isoparental embryos form hydatidiform moles and dermoid cysts.
Hydatidiform moles have been found to be homozygous and androgenetic, that is, missing
any maternal contribution to their genome. This type of mole is called a “complete mole” and
the most likely explanation for how these moles arise is that the nucleus of the ovum is possibly
lost or inactivated, and the duplication of a haploid sperm reconstitutes the diploid number, but
the complete mole is genetically homozygous (20). The absence of the maternal genome has a
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severe effect on the development of embryos and often results in a lack of any fetal tissues,
indicating that the paternal genome preferentially supports development of the extraembryonic
tissues and fails to support development of the fetus (21, 22).
Dermoids, on the other hand, are maternally derived diploids with no paternal genome
component, possibly resulting from an unfertilized oocyte. These cysts, called “benign ovarian
teratomas,” show disorganized fetal structures often including teeth, hair and bone tissues,
supporting the fact that the maternal genome is essential for fetal development but incapable of
supporting the development of embryos to term (14).
Another form of chromosomal disorders has been observed in triploid embryos. Diandric
triploids carry two paternal and one maternal chromosome, in which the possibility of early
cessation of fetal development is high, while digynic triploids carry two maternal and one
paternal chromosome and have a greater chance of survival (22).
Using experimental manipulations in mice, similar observations have been made, and thus, it
was concluded that successful embryogenesis requires a complete set of chromosomes from
both parents since they are complementary and indispensable.
Chromosome Deletion Syndromes: The phenotypes of various chromosome deletion
syndromes in humans have been reported over the last 30 years. The Prader-Willi Syndrome
has been recognized by hypotonia in infancy, obesity beginning in early childhood, mental
retardation and development of small hands and feet. In 1981, Ledbetter et al. found that four
out of five cases of PWS had lost the same small band near the centromere on chromosome 15
(23). Angelman's Syndrome is another disease that was described about 30 years ago. The
diagnosis is usually made before the age of five in children with almost complete failure to talk,
severe mental retardation, a jerky ataxia and inappropriate laughter. Case reports later
demonstrated that patients with the clinical characteristics of AS had the same cytogenetic
abnormalies as PWS patients (24, 25).
Both syndromes resulted from chromosomal deletions in bands 15q11-13 and the deletions
were indistinguishable. A possible role for genomic imprinting in producing the distinct
phenotypes was proposed when it was found that the deleted DNA in the two syndromes was
of opposite parental origin: when a 15q11-13 deletion occurs on the parental chromosome,
then the child will develop PWS, but when the deletion occurs on the maternal chromosome, the
child develops Angelman's Syndrome (14). Further studies of these syndromes suggested that
the corresponding maternal gene(s) in PWS, and the paternal gene(s) in AS should normally be
silent, that is, imprinted. As can be clearly seen in these disorders, a genetic contribution from
both the male and female parent is required for normal development.
Since then, some PWS patients with no chromosome deletions have also been reported and
studies indicated that these PWS patients surprisingly had two maternal chromosomes. In other
words, the lack of paternal genes on the long arm of chromosome 15 (at 15q11-13), possibly
due to the inheritance of two maternal chromosomes (maternal uniparental disomy), leads to
the development of PWS (26, 27). A similar event also leads to paternal UPD in Angelman's
Syndrome. This, however, appears to be rare (28, 29, 30).
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Single Gene Disorders: Studies of transgenic mice have demonstrated that the level of
expression of an inserted transgene depends on whether the gene sits on a maternal
chromosome or a paternal chromosome, indicating the possibility of single gene imprinting (16).
These studies, therefore, suggested that the expression of a gene responsible for a disease
possibly depends upon the sex of the parent of origin. It was then possible to understand the
remarkable pedigree patterns of some well-known dominantly inherited genetic disorders whose
observed patterns could not be explained by dominant or recessive inheritance.
When it was reconsidered, the Huntington's Disease, HC, was found to be a good example
of genomic imprinting. Clinical observations of patients suffering from this disease reported
that the severity or age of onset of symptoms is affected by parental origin: the age of onset of
Huntington's Disease is lower when the HC gene is inherited from the father rather than the
mother (19).
Following the recognition that severity of expression of the disease is affected by parental
origin, the phenomenon was related in a number of autosomal dominant disorders, such as
myotonic dystrophy, spinocerebellar ataxia and neurofibromatosis (types I and II), and it was
found that the parental effect is likely to play a role in all of them (22).
Genomic Imprinting in Tumorigenesis: The results of studies of familial cancer disorders
have suggested that genomic imprinting is also involved in tumorigenesis (31, 32).
Furthermore, the findings in studies of Beckwith-Wiedemann Syndrome (BWS) firmly
established the role of single gene imprinting in tumor syndromes (13). BWS is characterized by
the excessive growth of developing tissues, and a high percentage (64%) of patients develop
Wilms' Tumor, adrenocortical carcinoma and hepatoblastoma (33, 34). The finding of 11p
deletions in the somatic cells of some children with Wilms' Tumors revealed that the gene
responsible for the Wilms' Tumor is located on 11p. It has also been observed that the maternal
chromosome 11 was lost from some sporadic Wilms' Tumors. First, the classical "two-hit"
model for recessive oncogenesis was able to explain the case in Wilms' Tumor patients (35).
According to this model, in recessive tumors, both alleles of a gene functioning as a recessive
tumor suppressor are lost: one allele is mutated or microdeleted (the first hit), and the other
allele is lost possibly by somatic recombination or a large chromosomal deletion (the second hit)
(13).
The observation of preferential loss of heterozygosity (LOH) of a specific parental allele has
been reported in several childhood cancers patients, indicating that the maternal and paternal
chromosomes are not lost with the same frequency. For example, the maternal chromosomes
were much more frequently lost than the paternal chromosomes in Wilms' Tumor (loss in
chromosome 11p) and in osteosarcoma (loss in chromosome 13q). With this finding, the role
of genomic imprinting in cancer became more obvious. It was then postulated that the first hit
in Wilms' Tumor and in other embryonal tumors is the imprinting of a specific parental allele
which results in inactivation of the tumor suppressor gene. The chromosome loss caused by the
second hit then initiates growth of the tumor (22).
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While the inactivation hypothesis of the imprinted tumor suppressor gene in cancer may be
correct, an alternative hypothesis, suggesting a role of gene activation due to loss of imprinting,
was also proposed by Feinberg (13). As described by Feinberg, the gene activation model
suggests that a normal function of imprinting is to repress the expression of one copy of a
growth promoting gene. Thus, any disturbance in genomic imprinting will cause activation of
the transcriptionally repressed copy, resulting in tumor formation. In parallel with this
hypothesis, an abnormal expression of one particular gene, Igf2, was observed in about 70% of
Wilms' Tumor patients where both Igf2 alleles were expressed (36).
While further investigations are required to test which hypothesis is correct, there is now
enough evidence to prove that genomic imprinting is involved in tumorigenesis (37, 38).
The Proposed Mechanisms for Genomic Imprinting
Studies of the imprinted endogenous genes in mice revealed that the paternal and maternal
genomes must be marked differently so that the transcriptional machinery of the cell can
discriminate between the paternal and maternal alleles for directing the parental-specific
transcription in the developing organism. The precise mechanism(s) involved in this process
is/are still under investigation.
Sex-linked Dosage-sensitive Modifier Genes and Genomic Imprinting:
DNA heterochromatization has been proposed as one of the possible mechanisms for
genomic imprinting. According to this hypothesis, proposed by Sapienza, the modifier genes on
the sex chromosomes may act to bring about changes in chromatin structures as a part of the
imprinting process (39).
Although the mechanism of heterochromatization in the chromosomes of eukaryotes is
unclear, the phenomenon of position effect variegation has been studied in detail in Drosophila
(40). It has been determined that variegating position effects result from chromosomal
rearrangements that place wild-type genes adjacent to constitutive heterochromatin. The
compacted structure of heterochromatin is responsible for the repression of that particular wildtype gene's expression in some cells. Locke et al. suggested that heterochromatic domains are
constructed by the activity of modifier genes that encode for structural protein components of
heterochromatin. In Drosophila, two classes of modifiers (I and II) have been described. Class I
modifiers enhance variegation when duplicated, or suppress variegation when deficient. Class II
modifiers behave in a reciprocal fashion; they enhance when deficient but suppress when
duplicated (40).
Parallels between variegating position effects in Drosophila and the data from tumorigenesis
in mammals gave rise to the idea that the inactivation of imprinted genes may be accomplished
by the action of modifier genes through the formation of heterochromatic domains (39, 41,
42). According to this model, the gamete-of-origin dependent modification of the imprinted
gene is assumed to be accomplished by the positioning of modifier genes on the sex
chromosomes (X or Y) and also by their types (class I or II). For example, males carrying X-
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linked modifier type I will suppress variegation of a specific imprinted gene in their offspring
because they are hemizygous for the X-linked modifier (deficiency). However, females will
enhance variegation in their offspring since they carry two X chromosomes (duplication).
The observed variability in the expressivity of Huntington's Disease imprinted loci made this
disease a specific example of the application of this hypothesis. Sapienza gave several
explanations for the genetics of Huntington's Disease, and an answer to the question of how
such a large degree of variability is possible in the age of onset of the disease (39).
Allele-specific Replication Timing and Genomic Imprinting: Another mechanism
proposed for genomic imprinting is called allele-specific replication timing. In general, results
from studies of imprinted genes have suggested that genomic imprinting may also involve
regional control mechanisms. Examples of this include observation of imprinting mutations
affecting methylation imprints at multiple loci, the identification of PWS and AS patients carrying
several DNA segments with differential methylation patterns on the same chromosome,15, and
the positioning of Igf2 and H19 genes within a domain on mouse chromosome 7. However,
direct evidence for this hypothesis came from experiments on the replication timing of individual
imprinted genes and their flanking loci. When Kitsberg et al. examined the replication timing
patterns of the imprinted genes H19, Igf2, Igf2r and Snrpn in the mouse, an interesting
observation was made, that the paternal alleles of all imprinted genes replicated earlier than the
maternal alleles in each cell cycle (43). It is known that most genes on the maternal and paternal
homolog chromosomes replicate synchronously during the S phase in the cell cycle (44). In this
study, however, all known imprinted mouse genes and a number of flanking regions at each of
these genes showed asynchronous replication patterns (43). This has also been determined to
be true for human imprinted genes (45). These results suggested a close correlation between
genomic imprinting and the physical compartmentalization of the imprinted chromosomal
regions (called "the novel replication timing units"). However, it is not yet known how
differential DNA replication of imprinted gene regions and differential DNA methylation of
imprinted alleles are coordinated. Nevertheless, this data supports the fact that genomic
imprinting is a complicated process that requires multiple control mechanisms.
Gene-specific DNA Methylation and Genomic Imprinting: The methylation of CpG
dinucleotides in DNA has been suggested as a good candidate for the label that imprints DNA
because DNA methylation patterns are heritable and stable through subsequent cell generations,
but at the same time are dynamic during specific developmental stages.
In somatic cells, DNA methylation has been shown to play an important role in the process
of gene regulation by acting as a repressor of transcription. This modification is faithfully
inherited through cell divisions by the action of the DNA methyltransferase, while it can also be
reversed during DNA replication in the absence of the responsible enzyme (46). In the late
1980s, some evidence suggested that this modification (DNA methylation) might account for
genomic imprinting (47, 48).
The first experimental evidence supporting this hypothesis was that the examination of
several imprinted endogenous genes showed that these sequences were differentially
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methylated, and that the modification patterns were also parent specific. The H19 gene, for
example, was found to be methylated on the inactive paternal allele and unmethylated on the
active maternal allele in both mice and humans. Therefore, it was suggested that this allelespecific methylation functions as a mark to suppress transcription of the H19 paternal allele
(49). Less direct evidence for the involvement of methylation in imprinting was observed when
cells were exposed to the DNA methyltransferase inhibitor 5-azacytidine. Treatment of cells
containing two copies of the paternally derived H19 gene with this agent perturbed methylation,
and demethylation of H19 alleles resulted in reactivation of H19 transcription (50).
The best evidence for the role of DNA methylation in genomic imprinting is that the normal
expression patterns of all three imprinted genes (H19, Igf2 and Igf2r) were altered in mice
homozygous for DNA methyltransferase mutation (51). In this particular experiment, it was
shown that in the reduced levels of methlytransferase activity, the normally silent paternal H19
allele was expressed, whereas the normally active paternal Igf2 became silenced. Li et al.
however, found that the expression of the Igf2r gene, which is expressed exclusively from the
maternal allele, was almost the same in the methyltransferase mutant embryos as in the wildtype embryos, suggesting that the DNA methylation may not be the imprinting label for this
specific gene. Further experiments related to this gene indicated that Igf2r requires a greater
reduction in methyltransferase activity for its maternal allele to be silenced (51, 52). Although
the inability of methyltransferase mutant embryos to maintain normal regulation of imprinted
genes confirms the role of methylation in genomic imprinting, the results of these experiments
do not prove that methylation itself is the original imprint. Tycko argued that the observed
effects on imprinting in these mutant mice might be indirect since the demethylation was
generated in genome-wide fashion, and because of the potential for indirect effects, it is difficult
to separate cause from effect in relating CpG methylation to the transcriptional activity of
specific genes (50). In parallel with this idea, in this study, the possible deregulation of nonimprinted genes was not addressed. Moreover, it is also possible that other unknown imprinted
genes might be subjected to deregulation in methyltransferase mutant embryos and contribute
to the phenotype.
The majority of the imprinted genes are characterized by parent specific methylation in their
CpG islands. The Igf2r gene is an imprinted gene with an active maternal and inactive paternal
copy. In this gene, two distinct CpG islands show parental-origin specific methylation
differences: the paternally inactive Igf2r gene has a paternally methylated promoter region, and
it also has an intronic CpG-rich region (27-kilo bases downstream of the Igf2r promoter) that
is surprisingly highly methylated on the active maternal allele (53). The preferential methylation
of the expressed copy of the Igf2r gene is very unusual. Stöger et al. hypothesized that this
intronic island might act as a silencer on the paternal chromosome when it is not methylated by
binding a repressor protein (53).
In the case of Igf2 and H19, these genes are closely linked, but they are imprinted
reciprocally, that is, the paternal copy of the Igf2 and the maternal copy of H19 are expressed
during development (54). Two regions in this domain have been shown to be methylated in
different ways. First, the 3-kb region upstream of the Igf2 gene is methylated on the expressed
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paternal chromosome though the paternal allele of the Igf2 is the one normally expressed.
When Sasaki et al. found that the CpG island of the 3-kb region upstream of the Igf2 gene was
less methylated on the maternal chromosome, they suggested that this region could act as a
silencer on this chromosome, as has been suggested for the Igf2r gene (55). Interestingly, in
these experiments, no detectable differences in DNA methylation between the Igf2 parental
genes were observed, and the inactive maternal Igf2 retained a low level of transcription.
Second, it was suggested that the imprinting of H19 and Igf2 is linked, and the observed
methylation of the inactive paternal H19 promoter was proposed to be a controlling factor for
the expression of the paternal Igf2 gene. In this case, it was postulated that Igf2 and H19
compete for the putative enhancers (probably positioned downstream of the H19 gene) and the
enhancers may activate Igf2 expression when only the paternal H19 is methylated and therefore
inactive. According to this enhancer model, the unmethylated maternal H19 promoter has a
higher affinity for the enhancer, resulting in the expression of H19 (49).
It has been thought that the DNA modification pattern seen in the somatic cells is established
in the individual gametes and then inherited through development. If DNA methylation is the
primary label for imprinting, the differential methylation patterns must be established in the
individual gametes and must be maintained during early embryogenesis. For this purpose, the
methylation patterns of several endogenous imprinted genes have been followed during
gametogenesis and preimplantation embryogenesis, and results from these studies indicated that
the somatic methylation patterns cannot be derived from the gametes (56). For example, while
the small upstream CpG region of the H19 gene on the paternal chromosome was completely
unmethylated in sperm DNA, this locus was methylated in the late embryos. Furthermore, the
sites upstream of the Igf2 promoter were only partially methylated in sperm DNA, suggesting
that each individual embryo must be generated from a paternal Igf2 allele with a different
methylation pattern. These results indicated that these loci cannot provide a stable gametederived modification signals. Thus, the imprinted genes might be marked by some other
mechanism other than methylation. Moreover, it has been shown that the early fetal germ line
cells are subjected to the preimplantation demethylation process, and, at this stage, the parentspecific methylation patterns of imprinted genes are totally erased. Therefore, the differential
methylation patterns of imprinted genes seen in late embryonic and adult cells must be
reestablished, implying that something other than pre-existing methylation profiles might be
recognized by the methyltransferase enzyme (56).
In conclusion, the results from the studies presented here indicate that DNA methylation and
genomic imprinting are very closely associated. However, it is currently unclear whether
methylation functions in the establishment of imprinting or plays a secondary role in the
maintenance of the genomic imprinting. The regulation of imprinted genes, therefore, seems to
be a complex process, and the contribution of some other factors, such as trans- and cis-acting
elements, chromatin structure and the replication timing of individual imprinted gene loci might
be involved (57, 58).
However, it seems likely that the mechanism of genomic imprinting may eventually be
clarified with the help of ongoing studies of novel imprinted genes, such as the human MEST
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(59), ILK (60), KVLQT1 (61), putative TS (62) genes and the plant MEDEA gene (63), and also
with the help of studies of newly identified chromosome deletion (64), alteration (65) and
mutation sydromes (66) involving the genomic imprinting effect.
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